Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study (Q40816652)

24 September 2017

Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study (English)

1 reference

chronic renal insufficiency

24 September 2017

1 reference

1 reference

Szu-Chun Hung

1

1 reference

24 September 2017

Yu-Kang Chang

2

1 reference

24 September 2017

Jia-Sin Liu

3

1 reference

24 September 2017

Ko-Lin Kuo

4

1 reference

24 September 2017

Yu-Hsin Chen

5

1 reference

24 September 2017

Chih-Cheng Hsu

6

1 reference

24 September 2017

Der-Cherng Tarng

7

1 reference

24 September 2017

17 June 2015

1 reference

The Lancet: Diabetes & Endocrinology

24 September 2017

1 reference

24 September 2017

3

1 reference

24 September 2017

8

1 reference

24 September 2017

605-614

1 reference

Temporal trends in the prevalence of diabetic kidney disease in the United States

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin use and mortality among patients with diabetes and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin and other antidiabetic agents in renal failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Taiwan's new national health insurance program: genesis and experience so far.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Indications for propensity scores and review of their use in pharmacoepidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Clinical Pharmacokinetics of Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin overdose causes platelet mitochondrial dysfunction in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Association between mitochondrial dysfunction and severity and outcome of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Survival in critical illness is associated with early activation of mitochondrial biogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin action: concentrations matter.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Metformin improves healthspan and lifespan in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900123-0

7 January 2021

10.1016/S2213-8587(15)00123-0

Identifiers

DOI

1 reference

24 September 2017

1 reference